[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370155-105":59,"doc-detail-370155-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","factors-influencing-the-cost-effectiveness-of-radiofrequency-ablation-for-barretts-esophagus-with-low-grade-dysplasia-in-australia","Factors influencing the cost-effectiveness of radiofrequency ablation for Barrett’s esophagus with low-grade dysplasia in Australia","","Endoscopic eradication therapy using radiofrequency ablation (RFA) is evaluated as an alternative to surveillance for Barrett’s esophagus with low-grade dysplasia (LGD). A Markov model, grounded in an Australian longitudinal cohort (PROBE-NET), estimates incremental cost per quality-adjusted life year (QALY) gained for RFA versus endoscopic surveillance. Replacing surveillance with RFA yields fewer HGD cases and fewer EAC-related deaths, with an incremental cost-effectiveness ratio of AU$47,815 per QALY. Results are sensitive to EAC progression rate from LGD, utility values, and number of RFA sessions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/factors-influencing-the-cost-effectiveness-of-radiofrequency-ablation-for-barretts-esophagus-with-low-grade-dysplasia-in-australia/370155/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/factors-influencing-the-cost-effectiveness-of-radiofrequency-ablation-for-barretts-esophagus-with-low-grade-dysplasia-in-australia/370155.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of the study evaluating radiofrequency ablation (RFA) for Barrett’s esophagus with low-grade dysplasia (LGD)?","Question",{"text":112,"@type":113},"The study estimates whether RFA is cost-effective compared with endoscopic surveillance for LGD and identifies the factors that drive cost-effectiveness.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was cost-effectiveness modeled in the study?",{"text":117,"@type":113},"A decision analytic Markov model was built to estimate the incremental cost per quality-adjusted life year (QALY) gained for RFA versus endoscopic surveillance, using data from an Australian longitudinal cohort (PROBE-NET).",{"name":119,"@type":110,"acceptedAnswer":120},"Which parameters most affect the cost-effectiveness results?",{"text":121,"@type":113},"The model is sensitive to the rate of esophageal adenocarcinoma (EAC) progression from the LGD health state, the utility values, and the number of RFA sessions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370155,1790642196,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Diseases of the Esophagus (2025), 38, 1–7 [https://doi.org/10.1093/dote/doae095](https://doi.org/10.1093/dote/doae095)  \nOriginal Article  \nFactors influencing the cost-effectiveness of radiofrequency ablation for Barrett’s esophagus with low-grade dysplasia in Australia  \nLauren Caush, 1 Jody Church, 2 Stephen Goodall,2 Reginald V. Lord 1 , 3  \n1Department of Surgery, The University of Notre Dame School of Medicine, Sydney, Australia, 2Faculty of Health, Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia, and 3 Gastroesophageal Cancer Research Program, St. Vincent’s Centre for Applied Medical Research, Sydney, Australia  \n\n| SUMMARY. Endoscopic eradication therapy using radiofrequency ablation (RFA) is considered an acceptable alternative to surveillance monitoring for Barrett’s esophagus with low-grade dysplasia (LGD). This study aimed to estimate whether RFA for LGD is cost-effective and to determine which factors influence cost-effectiveness. A Markov model was developed to estimate the incremental cost per quality-adjusted life year (QALY) gained for RFA compared with endoscopic surveillance. An Australian longitudinal cohort study (PROBE-NET) provides the basis of the model. Replacing surveillance with RFA yields 10 fewer cases of HGD and 9 fewer esophageal adenocarcinoma (EAC)-related deaths per 1000 patients’ treatment, giving an average 0.192 QALYs at an additional cost of AU$9211 (e5689; US$6262) per patient (incremental cost-effectiveness ratio AU$47,815 per QALY). The model is sensitive to the rate of EAC from LGD health state, the utility values, and the number of RFA sessions. Hence, the incremental benefit ranges from 0.080 QALYs to 0.198 QALYs leading to uncertainty in the cost-effectiveness estimates. When the cancerous progression rate of LGD falls \u003C0.47% per annum, the costeffectiveness of RFA becomes questionable. RFA treatment of LGD provides significantly better clinical outcomes than surveillance. The additional cost of RFA is acceptable if the LGD to EAC rate is >0.47% per annum and no more than three RFA treatment sessions are provided. Accurate estimates of the risk of developing EAC in patients with LGD are needed to validate the analyses.\u003Cbr>KEY WORDS: Barrett’s esophagus, cost-effectiveness, economic evaluation, esophageal adenocarcinoma, radiofrequency ablation. |  |\n| --- | --- |\n| INTRODUCTION\u003Cbr>The presence and severity of dysplasia is the main factor influencing the risk of progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC) and guides the management of patients with this disease.1 Endoscopic eradication therapy (EET) by resection and often radiofrequency ablation (RFA) is the standard of care treatment for BE with high-grade dysplasia (HGD) .2–6\u003Cbr>For patients diagnosed with BE with low-grade dysplasia (LGD), EET using RFA is considered an acceptable alternative to surveillance monitoring, but there is uncertainty regarding the role of RFA versus surveillance for LGD due to the wide variation in the reported rate of progression from LGDtoHGD/EAC | in different studies, from \u003C1 .0% per year to > 10% per year.7–9 This wide range reflects pathologists’difficulty and variability in diagnosing LGD. This variability in pathological diagnosis could account for the outlying high progression rates if some of the LGD diagnoses would be classified as HGD by others.9 Overdiagnosis of LGD in cases that would be classified as non-dysplastic elsewhere may be a concern in other studies. Other complicating factors are that the progression rates for unifocal and multifocal LGD may differ, and that a diagnosis of LGD can be transient.\u003Cbr>Previous studies have found RFA to be costeffective 10–15 for LGD treatment. Our study extends knowledge on this topic by incorporating pooled RFA effectiveness results from three randomized controlled |\n\nAddress correspondence to: Dr. Jody Church, Faculty of Health, Centre for Health Economics Rese","cbCaikKZSXpBSC1C","https://ap.wps.com/l/cbCaikKZSXpBSC1C","pdf",612932,"English","# Summary\n# Introduction\n# Methods","[{\"question\":\"What is the purpose of the study evaluating radiofrequency ablation (RFA) for Barrett’s esophagus with low-grade dysplasia (LGD)?\",\"answer\":\"The study estimates whether RFA is cost-effective compared with endoscopic surveillance for LGD and identifies the factors that drive cost-effectiveness.\"},{\"question\":\"How was cost-effectiveness modeled in the study?\",\"answer\":\"A decision analytic Markov model was built to estimate the incremental cost per quality-adjusted life year (QALY) gained for RFA versus endoscopic surveillance, using data from an Australian longitudinal cohort (PROBE-NET).\"},{\"question\":\"Which parameters most affect the cost-effectiveness results?\",\"answer\":\"The model is sensitive to the rate of esophageal adenocarcinoma (EAC) progression from the LGD health state, the utility values, and the number of RFA sessions.\"}]","Factors influencing the cost-effectiveness of radiofrequency ablation for Barrett’s esophagus with low-grade dysplasia in Australia | PDF",1790187101,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd00b151ccb39971e564cf081357e8f3.webp",983,1296,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80cb097b504e907eafabaa9ff9452b8a.webp",982,1294,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/330a8728cf0c05e3e3340fd6bfb6126f.webp",981,1293,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82b6c9e0e6a44255b75bc1f6fd06e85f.webp",980,1292]